Market News

Alnylam Pharmaceuticals, Inc. (ALNY) Reaches $105.08 After 8.00% Up Move; Bares Capital Management Has Decreased Its Comscore (SCOR) Holding

comScore, Inc. (OTCMKTS:SCOR) Logo

Bares Capital Management Inc decreased Comscore Inc. (SCOR) stake by 4.57% reported in 2017Q4 SEC filing. Bares Capital Management Inc sold 114,700 shares as Comscore Inc. (SCOR)’s stock declined 12.19%. The Bares Capital Management Inc holds 2.40M shares with $68.33 million value, down from 2.51M last quarter. Comscore Inc. now has $1.13 billion valuation. It closed at $20.5 lastly. It is down 0.00% since May 14, 2017 and is . It has underperformed by 11.55% the S&P500.

The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a huge mover today! The stock increased 4.13% or $4.17 during the last trading session, reaching $105.08. About 453,498 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 150.73% since May 14, 2017 and is uptrending. It has outperformed by 139.18% the S&P500.The move comes after 6 months positive chart setup for the $10.56 billion company. It was reported on May, 14 by Barchart.com. We have $113.49 PT which if reached, will make NASDAQ:ALNY worth $845.04M more.

More news for comScore, Inc. (OTCMKTS:SCOR) were recently published by: Seekingalpha.com, which released: “comScore (SCOR) Q1 2018 Results – Earnings Call Transcript” on May 10, 2018. Seekingalpha.com‘s article titled: “ComScore names Wiener new CEO” and published on April 23, 2018 is yet another important article.

Bares Capital Management Inc increased National Instruments Corp. (NASDAQ:NATI) stake by 61,558 shares to 3.54M valued at $147.21M in 2017Q4. It also upped Costar Group (NASDAQ:CSGP) stake by 21,558 shares and now owns 621,563 shares. Markel Corp. (NYSE:MKL) was raised too.

Investors sentiment increased to 0.2 in 2017 Q4. Its up 0.20, from 0 in 2017Q3. It increased, as 1 investors sold SCOR shares while 4 reduced holdings. 0 funds opened positions while 1 raised stakes. 11.57 million shares or 2.73% less from 11.89 million shares in 2017Q3 were reported. Sit Inv Inc, a Minnesota-based fund reported 100 shares. The Florida-based Rgm Limited Com has invested 6.78% in comScore, Inc. (OTCMKTS:SCOR). Pnc Financial Serv Gp Inc invested in 106 shares. Teachers Retirement Systems Of The State Of Kentucky stated it has 5,680 shares. Primecap Mngmt Ca invested in 6.07 million shares or 0.13% of the stock. Bares Capital Management Inc, a Texas-based fund reported 2.40M shares. Markston Ltd Llc invested in 2,075 shares or 0.01% of the stock. Disciplined Growth Investors Mn holds 0.11% of its portfolio in comScore, Inc. (OTCMKTS:SCOR) for 187,709 shares. American Capital Management has invested 0.22% of its portfolio in comScore, Inc. (OTCMKTS:SCOR). 159,000 are held by Lapides Asset Mgmt Ltd. Panagora Asset Mgmt Incorporated reported 159 shares. Parametric Portfolio Assoc Lc holds 27,659 shares or 0% of its portfolio. 34,146 were accumulated by Messner And Smith Theme Value Invest Mngmt Limited Ca.

Among 12 analysts covering ComScore (NASDAQ:SCOR), 5 have Buy rating, 0 Sell and 7 Hold. Therefore 42% are positive. ComScore had 21 analyst reports since August 5, 2015 according to SRatingsIntel. On Wednesday, September 16 the stock rating was initiated by William Blair with “Outperform”. The firm has “Positive” rating given on Monday, August 10 by Susquehanna. The company was downgraded on Tuesday, March 8 by Macquarie Research. The rating was downgraded by Goldman Sachs on Friday, July 31 to “Neutral”. The stock of comScore, Inc. (OTCMKTS:SCOR) has “Hold” rating given on Tuesday, March 27 by Jefferies. Susquehanna downgraded the stock to “Neutral” rating in Wednesday, June 29 report. The rating was maintained by Needham on Wednesday, January 20 with “Buy”. Telsey Advisory Group maintained the shares of SCOR in report on Thursday, February 18 with “Outperform” rating. The company was downgraded on Tuesday, June 28 by Telsey Advisory Group. JP Morgan downgraded the shares of SCOR in report on Tuesday, January 5 to “Neutral” rating.

Among 24 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 6 Hold. Therefore 71% are positive. Alnylam Pharmaceuticals had 107 analyst reports since August 7, 2015 according to SRatingsIntel. Chardan Capital Markets maintained the stock with “Buy” rating in Monday, December 19 report. The rating was maintained by Leerink Swann on Thursday, September 21 with “Market Perform”. The company was initiated on Tuesday, August 11 by FBR Capital. Stifel Nicolaus maintained it with “Hold” rating and $5600 target in Friday, August 11 report. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Outperform” rating by Credit Suisse on Tuesday, March 13. The rating was downgraded by Leerink Swann to “Mkt Perform” on Thursday, October 6. Jefferies maintained it with “Buy” rating and $86 target in Friday, August 5 report. The rating was downgraded by TheStreet to “Hold” on Saturday, August 22. Needham maintained the shares of ALNY in report on Friday, November 3 with “Buy” rating. The company was maintained on Friday, August 28 by JMP Securities.

Since January 4, 2018, it had 0 buys, and 10 sales for $38.04 million activity. Another trade for 88,554 shares valued at $12.67 million was sold by Vaishnaw Akshay. 17,117 shares were sold by Ausiello Dennis A, worth $2.57 million. 36,745 shares valued at $4.84 million were sold by Mason Michael on Thursday, January 4. 1,562 shares valued at $234,033 were sold by KEATING LAURIE on Tuesday, March 20. SHARP PHILIP A sold 15,000 shares worth $2.24 million. Greenstreet Yvonne also sold $985,958 worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Monday, March 26. 38,460 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares with value of $5.50 million were sold by Greene Barry E.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Seekingalpha.com which released: “Alnylam Pharmaceuticals: Hitting The Next Growth Curve” on April 25, 2018, also Seekingalpha.com with their article: “Alnylam Pharmaceuticals (ALNY) Q1 2018 Results – Earnings Call Transcript” published on May 04, 2018, Nasdaq.com published: “Ionis Pharmaceuticals Prepares for Launch” on May 09, 2018. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Bizjournals.com and their article: “Boston biotech entrepreneur Christoph Westphal launches new startup” published on May 02, 2018 as well as Globenewswire.com‘s news article titled: “Consolidated Research: 2018 Summary Expectations for STORE Capital, Microvision, International Game Technology …” with publication date: May 11, 2018.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *